drugset / Trial / NCT03587038
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a pilot study exploring the potential benefit of adding OKN-007 with Temozolomide for treatment in patients with malignant Glioblastoma undergoing adjuvant concomitant radiotherapy. This drug combination is expected to have an anti-cancer effect in patients who have experienced disease progression after first line treatment.
Timeline
- Start
- 2018-09-03
- Primary completion
- 2020-12-23
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DISUFENTON | Small molecule | 60 mg/kg | Intravenous |
| Subject | Temozolomide | Small molecule | 75 mg/m2 | Oral |